Atea Pharmaceuticals' Cash Burn Rate Raises Concerns Amid Unprofitability

Atea Pharmaceuticals has a cash runway of about 2.5 years, with US$329m in cash and a cash burn of US$134m over the trailing twelve months. The company's cash burn has increased by 5.7% in the last year, suggesting it is investing more in its business. While Atea Pharmaceuticals has not generated revenue in the last year, it has the potential to raise further capital through share issuance or debt.